Compare GeneDx Holdings Corp (WGS) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GeneDx Holdings Corp vs Xpeng Inc - ADR — how do they compare? GeneDx Holdings Corp trades at $61.92 (market cap $1.80B), while Xpeng Inc - ADR trades at $13.35 (market cap $12.96B). The key difference: Xpeng Inc - ADR is far larger — about 7.2× GeneDx Holdings Corp's market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, Xpeng Inc - ADR nearer its low. Which is the better fit depends on your goals.
| WGS | XPEV | |
|---|---|---|
Market Cap | $1.80B | $12.96B |
Sector | Technology | Consumer Cyclical |
52-Week High | $167.51 | $28.07 |
52-Week Low | $34.51 | $12.09 |
Enterprise Value | $1.80B | $15.07B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GeneDx Holdings (WGS) trades at $60.65, down 4.46% today, amid a bearish technical signal and multiple class-action lawsuits alleging securities fraud. The stock shows weak fundamentals with a negative net income margin of -17.58% and ROE of -30.42%, though it beat EPS estimates in two of the last three quarters. Revenue grew to $427.54M in 2025 but profitability remains a challenge, with a high EV/EBITDA of 161.17 indicating stretched valuation relative to earnings.
Despite a 90.9% analyst buy rating and a $75.40 consensus price target, significant risks from litigation and persistent losses cloud the outlook. The stock faces near-term pressure from legal overhangs, while operational cash flow turned negative in 2026. Investors should weigh high analyst optimism against substantial fundamental and legal headwinds before considering a position.
XPeng (XPEV) trades at $13.33, down 1.52% today, with a bearish technical signal and neutral oscillators. Revenue grew to $76.72B in 2025, but net income remained negative at -$1.14B, with improving margins. Recent news highlights global expansion, including the L03 SUV launch in Munich and Robotaxi testing, while Q2 2026 deliveries of 103,295 vehicles beat expectations, signaling demand recovery.
The stock offers upside to the $17.00 analyst target but faces risks from intense EV competition and persistent losses. Investor sentiment is mixed, with 64.7% of analysts rating it Buy, yet technical trends and cash flow volatility warrant caution. Key catalysts include new model launches and international growth, but profitability remains a critical hurdle.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
